Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?
This retrospective case-control study aimed to compare 30 versus 40 W power of CO 2 laser for the therapy of genitourinary syndrome of menopause (GSM). Postmenopausal women with severe intensity of dyspareunia and dryness were eligible to be included in this study. Primary outcomes were dyspareunia...
Gespeichert in:
| Veröffentlicht in: | Lasers in medical science 2017-11, Vol.32 (8), p.1865-1872 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1872 |
|---|---|
| container_issue | 8 |
| container_start_page | 1865 |
| container_title | Lasers in medical science |
| container_volume | 32 |
| creator | Pitsouni, Eleni Grigoriadis, Themos Falagas, Matthew Tsiveleka, Angeliki Salvatore, Stefano Athanasiou, Stavros |
| description | This retrospective case-control study aimed to compare 30 versus 40 W power of CO
2
laser for the therapy of genitourinary syndrome of menopause (GSM). Postmenopausal women with severe intensity of dyspareunia and dryness were eligible to be included in this study. Primary outcomes were dyspareunia and dryness. Secondary outcomes were itching/burning, dysuria, frequency and urgency, Female Sexual Function Index (FSFI), vaginal maturation value (VMV), and Vaginal Health Index Score (VHIS). One laser therapy was applied every month for 3 months. Outcomes were evaluated at baseline and 1 month following the 3rd therapy. Fifty (25 per group) women were included in this study. In the 30-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.0 ± 1.9, 5.9 ± 2.0, 16.6 ± 6.7, 29.9 ± 13.0, and 11.0 ± 2.9, respectively (within group comparisons all
p
|
| doi_str_mv | 10.1007/s10103-017-2293-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1925890921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1925890921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-bd7f3311e478750f3b9671cd8c8b6162eea7eb96cf4661a80c8958a09fc1b3333</originalsourceid><addsrcrecordid>eNp1kMtKxDAUhoMoOI4-gLuAGzfVnKaX1I3I4A1GZqPoLqSZk7FD29SkVeZtfBafzJRxIYJZnMDh-w_8HyHHwM6AsfzcAwPGIwZ5FMcFj8QOmUDC0yhjycsumbA4E5EoYtgnB96vWQAz4BOCD5V2VpW16qt3pMYp3Ve2VTWdLWJaK4-OGuto_4p0hW3V28FVrXIb6jft0tkGqTW0wdZ2avB4QTv7ESJhxxkNuYR9fT5fHpI9o2qPRz__lDzdXD_O7qL54vZ-djWPdAJpH5XL3HAOgEku8pQZXhZZDnoptCgzyGJElWPYaZNkGSjBtChSoVhhNJQ8vCk53d7tnH0b0PeyqbzGulYt2sFLKOJUFCxoCOjJH3QdqoXiI5VykYcxHoQtFSR579DIzlVNqC-ByVG83IqXwaccxUsRMvE24wPbrtD9uvxv6Bts04Ut</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1953879533</pqid></control><display><type>article</type><title>Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?</title><source>Springer Nature - Complete Springer Journals</source><creator>Pitsouni, Eleni ; Grigoriadis, Themos ; Falagas, Matthew ; Tsiveleka, Angeliki ; Salvatore, Stefano ; Athanasiou, Stavros</creator><creatorcontrib>Pitsouni, Eleni ; Grigoriadis, Themos ; Falagas, Matthew ; Tsiveleka, Angeliki ; Salvatore, Stefano ; Athanasiou, Stavros</creatorcontrib><description>This retrospective case-control study aimed to compare 30 versus 40 W power of CO
2
laser for the therapy of genitourinary syndrome of menopause (GSM). Postmenopausal women with severe intensity of dyspareunia and dryness were eligible to be included in this study. Primary outcomes were dyspareunia and dryness. Secondary outcomes were itching/burning, dysuria, frequency and urgency, Female Sexual Function Index (FSFI), vaginal maturation value (VMV), and Vaginal Health Index Score (VHIS). One laser therapy was applied every month for 3 months. Outcomes were evaluated at baseline and 1 month following the 3rd therapy. Fifty (25 per group) women were included in this study. In the 30-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.0 ± 1.9, 5.9 ± 2.0, 16.6 ± 6.7, 29.9 ± 13.0, and 11.0 ± 2.9, respectively (within group comparisons all
p
< 0.001). In the 40-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.5 ± 2.0, 5.2 ± 2.5, 14.8 ± 7.1, 25.0 ± 13.4, and 10.5 ± 4.1, respectively (within-group comparisons, all
p
≤ 0.001). Comparison between 30 and 40 W revealed that mean improvement or presence of all GSM symptoms and clinical signs was not statistically significant different. CO
2
laser therapy may improve GSM symptoms and clinical signs. This improvement did not seem to associate to power of 30 or 40 W.</description><identifier>ISSN: 0268-8921</identifier><identifier>EISSN: 1435-604X</identifier><identifier>DOI: 10.1007/s10103-017-2293-8</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Burning ; Carbon dioxide ; Carbon dioxide lasers ; Clinical outcomes ; Dentistry ; Gynecology ; Itching ; Lasers ; Medicine ; Medicine & Public Health ; Menopause ; Optical Devices ; Optics ; Original Article ; Photonics ; Post-menopause ; Pruritus ; Quantum Optics ; Statistical analysis ; Therapy ; Vagina</subject><ispartof>Lasers in medical science, 2017-11, Vol.32 (8), p.1865-1872</ispartof><rights>Springer-Verlag London Ltd. 2017</rights><rights>Lasers in Medical Science is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-bd7f3311e478750f3b9671cd8c8b6162eea7eb96cf4661a80c8958a09fc1b3333</citedby><cites>FETCH-LOGICAL-c415t-bd7f3311e478750f3b9671cd8c8b6162eea7eb96cf4661a80c8958a09fc1b3333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10103-017-2293-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10103-017-2293-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Pitsouni, Eleni</creatorcontrib><creatorcontrib>Grigoriadis, Themos</creatorcontrib><creatorcontrib>Falagas, Matthew</creatorcontrib><creatorcontrib>Tsiveleka, Angeliki</creatorcontrib><creatorcontrib>Salvatore, Stefano</creatorcontrib><creatorcontrib>Athanasiou, Stavros</creatorcontrib><title>Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?</title><title>Lasers in medical science</title><addtitle>Lasers Med Sci</addtitle><description>This retrospective case-control study aimed to compare 30 versus 40 W power of CO
2
laser for the therapy of genitourinary syndrome of menopause (GSM). Postmenopausal women with severe intensity of dyspareunia and dryness were eligible to be included in this study. Primary outcomes were dyspareunia and dryness. Secondary outcomes were itching/burning, dysuria, frequency and urgency, Female Sexual Function Index (FSFI), vaginal maturation value (VMV), and Vaginal Health Index Score (VHIS). One laser therapy was applied every month for 3 months. Outcomes were evaluated at baseline and 1 month following the 3rd therapy. Fifty (25 per group) women were included in this study. In the 30-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.0 ± 1.9, 5.9 ± 2.0, 16.6 ± 6.7, 29.9 ± 13.0, and 11.0 ± 2.9, respectively (within group comparisons all
p
< 0.001). In the 40-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.5 ± 2.0, 5.2 ± 2.5, 14.8 ± 7.1, 25.0 ± 13.4, and 10.5 ± 4.1, respectively (within-group comparisons, all
p
≤ 0.001). Comparison between 30 and 40 W revealed that mean improvement or presence of all GSM symptoms and clinical signs was not statistically significant different. CO
2
laser therapy may improve GSM symptoms and clinical signs. This improvement did not seem to associate to power of 30 or 40 W.</description><subject>Burning</subject><subject>Carbon dioxide</subject><subject>Carbon dioxide lasers</subject><subject>Clinical outcomes</subject><subject>Dentistry</subject><subject>Gynecology</subject><subject>Itching</subject><subject>Lasers</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Menopause</subject><subject>Optical Devices</subject><subject>Optics</subject><subject>Original Article</subject><subject>Photonics</subject><subject>Post-menopause</subject><subject>Pruritus</subject><subject>Quantum Optics</subject><subject>Statistical analysis</subject><subject>Therapy</subject><subject>Vagina</subject><issn>0268-8921</issn><issn>1435-604X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kMtKxDAUhoMoOI4-gLuAGzfVnKaX1I3I4A1GZqPoLqSZk7FD29SkVeZtfBafzJRxIYJZnMDh-w_8HyHHwM6AsfzcAwPGIwZ5FMcFj8QOmUDC0yhjycsumbA4E5EoYtgnB96vWQAz4BOCD5V2VpW16qt3pMYp3Ve2VTWdLWJaK4-OGuto_4p0hW3V28FVrXIb6jft0tkGqTW0wdZ2avB4QTv7ESJhxxkNuYR9fT5fHpI9o2qPRz__lDzdXD_O7qL54vZ-djWPdAJpH5XL3HAOgEku8pQZXhZZDnoptCgzyGJElWPYaZNkGSjBtChSoVhhNJQ8vCk53d7tnH0b0PeyqbzGulYt2sFLKOJUFCxoCOjJH3QdqoXiI5VykYcxHoQtFSR579DIzlVNqC-ByVG83IqXwaccxUsRMvE24wPbrtD9uvxv6Bts04Ut</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Pitsouni, Eleni</creator><creator>Grigoriadis, Themos</creator><creator>Falagas, Matthew</creator><creator>Tsiveleka, Angeliki</creator><creator>Salvatore, Stefano</creator><creator>Athanasiou, Stavros</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7SP</scope><scope>7U5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H8D</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>L7M</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20171101</creationdate><title>Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?</title><author>Pitsouni, Eleni ; Grigoriadis, Themos ; Falagas, Matthew ; Tsiveleka, Angeliki ; Salvatore, Stefano ; Athanasiou, Stavros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-bd7f3311e478750f3b9671cd8c8b6162eea7eb96cf4661a80c8958a09fc1b3333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Burning</topic><topic>Carbon dioxide</topic><topic>Carbon dioxide lasers</topic><topic>Clinical outcomes</topic><topic>Dentistry</topic><topic>Gynecology</topic><topic>Itching</topic><topic>Lasers</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Menopause</topic><topic>Optical Devices</topic><topic>Optics</topic><topic>Original Article</topic><topic>Photonics</topic><topic>Post-menopause</topic><topic>Pruritus</topic><topic>Quantum Optics</topic><topic>Statistical analysis</topic><topic>Therapy</topic><topic>Vagina</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pitsouni, Eleni</creatorcontrib><creatorcontrib>Grigoriadis, Themos</creatorcontrib><creatorcontrib>Falagas, Matthew</creatorcontrib><creatorcontrib>Tsiveleka, Angeliki</creatorcontrib><creatorcontrib>Salvatore, Stefano</creatorcontrib><creatorcontrib>Athanasiou, Stavros</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Electronics & Communications Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Aerospace Database</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Lasers in medical science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pitsouni, Eleni</au><au>Grigoriadis, Themos</au><au>Falagas, Matthew</au><au>Tsiveleka, Angeliki</au><au>Salvatore, Stefano</au><au>Athanasiou, Stavros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?</atitle><jtitle>Lasers in medical science</jtitle><stitle>Lasers Med Sci</stitle><date>2017-11-01</date><risdate>2017</risdate><volume>32</volume><issue>8</issue><spage>1865</spage><epage>1872</epage><pages>1865-1872</pages><issn>0268-8921</issn><eissn>1435-604X</eissn><abstract>This retrospective case-control study aimed to compare 30 versus 40 W power of CO
2
laser for the therapy of genitourinary syndrome of menopause (GSM). Postmenopausal women with severe intensity of dyspareunia and dryness were eligible to be included in this study. Primary outcomes were dyspareunia and dryness. Secondary outcomes were itching/burning, dysuria, frequency and urgency, Female Sexual Function Index (FSFI), vaginal maturation value (VMV), and Vaginal Health Index Score (VHIS). One laser therapy was applied every month for 3 months. Outcomes were evaluated at baseline and 1 month following the 3rd therapy. Fifty (25 per group) women were included in this study. In the 30-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.0 ± 1.9, 5.9 ± 2.0, 16.6 ± 6.7, 29.9 ± 13.0, and 11.0 ± 2.9, respectively (within group comparisons all
p
< 0.001). In the 40-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.5 ± 2.0, 5.2 ± 2.5, 14.8 ± 7.1, 25.0 ± 13.4, and 10.5 ± 4.1, respectively (within-group comparisons, all
p
≤ 0.001). Comparison between 30 and 40 W revealed that mean improvement or presence of all GSM symptoms and clinical signs was not statistically significant different. CO
2
laser therapy may improve GSM symptoms and clinical signs. This improvement did not seem to associate to power of 30 or 40 W.</abstract><cop>London</cop><pub>Springer London</pub><doi>10.1007/s10103-017-2293-8</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-8921 |
| ispartof | Lasers in medical science, 2017-11, Vol.32 (8), p.1865-1872 |
| issn | 0268-8921 1435-604X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1925890921 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Burning Carbon dioxide Carbon dioxide lasers Clinical outcomes Dentistry Gynecology Itching Lasers Medicine Medicine & Public Health Menopause Optical Devices Optics Original Article Photonics Post-menopause Pruritus Quantum Optics Statistical analysis Therapy Vagina |
| title | Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T10%3A27%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microablative%20fractional%20CO2%20laser%20for%20the%20genitourinary%20syndrome%20of%20menopause:%20power%20of%2030%20or%2040%C2%A0W?&rft.jtitle=Lasers%20in%20medical%20science&rft.au=Pitsouni,%20Eleni&rft.date=2017-11-01&rft.volume=32&rft.issue=8&rft.spage=1865&rft.epage=1872&rft.pages=1865-1872&rft.issn=0268-8921&rft.eissn=1435-604X&rft_id=info:doi/10.1007/s10103-017-2293-8&rft_dat=%3Cproquest_cross%3E1925890921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1953879533&rft_id=info:pmid/&rfr_iscdi=true |